sb 203580 has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachem, M; Chen, G; Henne-Bruns, D; Kornmann, M; Liu, Z; Schmidt, B; Tian, X; Zhou, S | 1 |
1 other study(ies) available for sb 203580 and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.
Topics: Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Culture Media, Conditioned; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neoplasm Proteins; Osteonectin; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Paracrine Communication; Phenotype; Protein Isoforms; Pyridines; Receptor, Fibroblast Growth Factor, Type 1; Recombinant Fusion Proteins | 2010 |